Navigation Links
TGen Dr. Michael Barrett awarded $200,000 grant at national cancer conference in San Diego
Date:4/9/2014

PHOENIX, Ariz. April 8, 2014 The Pancreatic Cancer Action Network and the American Association for Cancer Research (AACR) awarded a $200,000 grant today to Dr. Michael Barrett of the Translational Genomics Research Institute (TGen).

Dr. Barrett, an Associate Professor in TGen's Clinical Translational Research Division, was one of 14 "outstanding scientists" across the nation named to receive a total of $5 million in grants for pancreatic cancer research.

The grants were announced during the AACR Annual Meeting 2014 in San Diego, April 5-9. With more than 34,000 members, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research.

Specifically, Dr. Barrett was one of five scientists to receive a 2014 Pancreatic Cancer Action Network-AACR Innovative Grant, "intended to promote the development and study of novel ideas and approaches in basic, translational, clinical, or epidemiological research that have direct application and relevance to pancreatic cancer."

Dr. Barrett's project, "Genomic drivers of therapeutic responses in metastatic disease," will investigate the molecular underpinnings of how and why pancreatic cancer spreads to other parts of the body.

"The fundamental hypothesis of this application is that distinct clonal tumor populations that arise during the natural history of pancreatic cancer mediate the clinical responses in patients with metastatic pancreatic cancer," Dr. Barrett said.

"The vision of our work is to bring together advanced genome technologies and the clinical resources available through TGen and our various collaborators to make an immediate impact in the lives of patients with pancreatic cancer and other malignancies," said Dr. Barrett, who also is a consultant with the Mayo Clinic Cancer Center-Arizona.

The grants support research into high-priority areas in an effort to reach the Pancreatic Cancer Action Network's goal to double pancreatic cancer survival by 2020.

"The most promising science has been selected for funding through a rigorous peer-review process. This year's grant recipients hail from leading institutions throughout the country and range from early career investigators continuing to build the field of pancreatic cancer leaders to more senior scientists," said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. "Their collective efforts have the potential to answer important questions that could lead to significant scientific advances for pancreatic cancer, and ultimately improve patient outcomes. We look forward to working with our new grantees and welcoming them to our team."

Pancreatic cancer annually takes the lives of more than 38,000 Americans, making it the fourth leading cause of cancer death in the U.S. A staggering 75 percent of those diagnosed die within the first year, and only 6 percent survive more than five years.

"Pancreatic cancer is among the most deadly of cancers," said Margaret Foti, Ph.D., M.D. (h.c.), and Chief Executive Officer of AACR. "With death rates steadily climbing over the past decade, more research into pancreatic cancer is urgently needed. The AACR is, therefore, proud to be partnering with the Pancreatic Cancer Action Network to support cutting-edge scientific research projects that have the potential to lead to major breakthroughs in the prevention, detection, and treatment of this devastating disease."


'/>"/>
Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts
2. Anne Glover and Sir Michael Stratton to meet the press at The EMBO Meeting 2013 in Amsterdam
3. Brupbacher Prize goes to cancer researcher Michael Karin
4. Researchers and company from Luxembourg awarded a grant from Michael J. Fox Foundation
5. Michael Barnett of Boston College named Professor of the Year for Massachusetts
6. Michael J. Fox Foundation grant to Dr. Samuel Young will provide Parkinsons drug development tools
7. AnaptysBio Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
8. Researchers find first evidence for a genetic cause for Barretts oesophagus
9. UCLA scientist awarded $3 million to fund research into proteins affecting the kidney
10. Simon Levin, Ph.D., awarded prestigious 2014 Tyler Prize for Environmental Achievement
11. Heidelberg researcher awarded Animal Welfare Prize of the German Research Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... -- PMD Healthcare announces the release of its new ... (WMS), a remote, real-time lung health monitoring and management ... a Medical Device, Digital Health, and Chronic Care Management ... solutions that empower people to improve their healthcare and ... the first ever personal spirometer, Spiro PD, which was ...
(Date:3/13/2017)... , March 13, 2017 Future of security: Biometric Face ... ... DERMALOGs Face Matching enables to match face pictures against ... basis to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching ...
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
(Date:3/22/2017)... COPENHAGEN, Denmark , March 22, 2017 /PRNewswire/ ... that utilizes its innovative TransCon technology to address ... announced financial results for the full year ended ... a significant year for our company as we ... become a leading, integrated rare disease company with ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... 22, 2017 MarketNewsUpdates.com News Commentary  ... The traditional ... being pressured as of late due to the rise of ... has a dramatic impact on patient,s quality of life as ... for identifying new forms of opioid formulations that prevent abuse. ...
Breaking Biology Technology: